• Investing
  • Stock
  • Editor’s Pick
  • Economy
The Significant Deals
Stock

Catalent CEO to remain in charge of contract drugmaker after Novo Holdings’ buyout

by October 21, 2024
written by October 21, 2024

(Reuters) – Catalent (NYSE:CTLT) CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker after it is acquired by Novo Holdings, the controlling shareholder of weight-loss drug manufacturer Novo Nordisk (NYSE:NVO).

Maselli’s open letter comes on the back of criticism over Novo Holding’s $16.5-billion acquisition of Catalent, which U.S. consumer groups said last week could threaten competition in weight-loss drugs and cutting-edge gene therapies. The groups have asked the U.S. Federal Trade Commission to block the deal.

Catalent is a manufacturing partner of Danish company Novo for Wegovy, its popular and highly effective weight-loss drug from the GLP-1 class which some analysts predict could become a $150 billion market by 2030. It also makes Sarepta Therapeutics (NASDAQ:SRPT)’ gene therapy Elevidys and others.

In response to the criticism, CEO Maselli reiterated in a letter to the company’s customers that Catalent will continue to operate as an independent contract drugmaker.

“I want to be clear: our commitments to you will not change, your products will remain our focus and your proprietary information will be protected.”

Maselli has been Catalent’s CEO for over two years, and during his tenure the company conducted a strategic review as part of a settlement with activist investor Elliott Investment Management, which had been pushing for changes following manufacturing problems and declining revenue.

The deal with Novo Holding has secured approval from Brazil’s antitrust regulator, but is awaiting clearances in Europe and the United States.

Earlier this month, U.S. Senator Elizabeth Warren also asked the Federal Trade Commision to closely scrutinize the acquisition, and block the deal if the regulator finds it illegal.

Catalent said on Monday it would continue to offer fill and finish services for sterile products for large and small molecules, including gene and cell therapies.

This post appeared first on investing.com
0 comment
0
FacebookTwitterPinterestEmail

previous post
Factbox-Airlines suspend flights as Middle East tensions rise
next post
Boeing shares rise after labor offer but analysts wary of worker pushback

You may also like

BASF results down on impairments, restructuring

January 27, 2025

European chipmakers slump as traders gauge DeepSeek AI...

January 27, 2025

Nasdaq futures tumble as China’s AI push rattles...

January 27, 2025

China Vanke’s CEO, chairman resign amid growing liquidity...

January 27, 2025

Fuji Media, rocked by sexual misconduct allegations, says...

January 27, 2025

Italy’s MPS shares fall ahead of Mediobanca board...

January 27, 2025

British Land stock drops following stake sale

January 27, 2025

UMG shares rally after new multi-year pact with...

January 27, 2025

BASF shares indicated 3% lower as impairments drag...

January 27, 2025

Ryanair cuts 2026 traffic forecast amid ongoing Boeing...

January 27, 2025
Fill Out & Get More Relevant News








    Stay ahead of the market and unlock exclusive trading insights & timely news. We value your privacy - your information is secure, and you can unsubscribe anytime. Gain an edge with hand-picked trading opportunities, stay informed with market-moving updates, and learn from expert tips & strategies.

    Recent Posts

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks

      June 26, 2025
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

      June 26, 2025
    • Bumble shares jump 26% as dating company plans to axe 30% of workforce

      June 26, 2025
    • Small-business AI use is lagging, but one firm is channeling Sherlock Holmes and knocking out ‘grunt work’

      June 25, 2025

    Categories

    • Economy (245)
    • Editor's Pick (3,646)
    • Investing (534)
    • Stock (6,426)

    Latest News

    • Divided Fed proposes rule to ease capital requirements for big Wall Street banks
    • Women’s Tennis Association extends media rights deal with Tennis Channel through 2032

    Popular News

    • Private equity faces an exit problem in Europe as bigger deals beckon
    • US FDA cited animal lab at Musk’s Neuralink for ‘objectionable conditions’

    About The Significant deals

    • Privacy Policy
    • Terms & Conditions

    Copyright © 2025 thesignificantdeals.com | All Rights Reserved

    The Significant Deals
    • Investing
    • Stock
    • Editor’s Pick
    • Economy